P1533: TRIAL IN PROGRESS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PARSACLISIB IN PATIENTS WITH PRIMARY WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Main Authors: | W. Barcellini, K. Butler, S. Moran, K. Bibeau, I. Dzhindzhikhashvili, S. Wei, U. Jäger |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000848988.44172.ff |
Similar Items
-
S286: LONG-TERM EFFICACY AND SAFETY RESULTS FROM AN ONGOING OPEN-LABEL PHASE 2 STUDY OF PARSACLISIB FOR THE TREATMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)
by: W. Barcellini, et al.
Published: (2022-06-01) -
Treatment of autoimmune hemolytic anemias
by: Alberto Zanella, et al.
Published: (2014-10-01) -
The Changing Landscape of Autoimmune Hemolytic Anemia
by: Wilma Barcellini, et al.
Published: (2020-06-01) -
Bortezomib in autoimmune hemolytic anemia and beyond
by: Raffaella Pasquale, et al.
Published: (2021-11-01) -
Immunotherapy Treatments of Warm Autoimmune Hemolytic Anemia
by: Bainan Liu, et al.
Published: (2013-01-01)